idelalisib and Abnormal-Karyotype

idelalisib has been researched along with Abnormal-Karyotype* in 1 studies

Trials

1 trial(s) available for idelalisib and Abnormal-Karyotype

Article	Year
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia, 2020, Volume: 34, Issue:1 Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Purines; Quinazolinones; Rituximab; Treatment Outcome	2020

Article

Year

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.

Leukemia, 2020, Volume: 34, Issue:1

Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Purines; Quinazolinones; Rituximab; Treatment Outcome

2020